UK prostate cancer market is forecast to grow at a CAGR of 9.7% during the forecast period. The high incidence of prostate cancer is the major factor for augmenting the demand for prostate cancer diagnostics services and therapeutics in the country. As per the World Health Organization, around 56,000 new cases of prostate cancer were registered in 2018. It is the most common cancer in the country with around 24% of the overall new cancer cases in men. The 5-year prevalence in the country due to prostate cancer is around 206,000 in 2018. 

In UK, prostate cancer is the second largest cause of cancer mortalities with around 13,000 mortalities in 2018. This is primarily due to the increasing aging population of UK. As per Cancer Research UK, more than half (54%) of prostate cancer cases in the UK each year are diagnosed in males aged 70 and over of age. Moreover, incidence rates for prostate cancer are projected to rise by 12% in the UK between 2014 and 2035 and 1 in 8 men will be diagnosed with prostate cancer during their lifetime in the country. Prostate cancer is most common in black males, then White males and least common in Asian males. 

UK prostate cancer diagnostic and therapeutics market has been studied on the basis of diagnostic techniques and therapeutics. By diagnosis technique, prostate biopsy is expected to hold a major market share during the forecast period. By therapeutics, chemotherapy is expected to have a major market share in the country. The companies which are contributing significantly in the market include Abbott Laboratories, AbbVie Products, LLC, AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Co., GlaxoSmithKline PLC, Johnson & Johnson, Pfizer Inc., Siemens Healthcare AG, and others. The market players are considerably contributing to the market growth by the adoption of various growth strategies including new product launch, merger, and acquisition, collaborations with government, and technological advancements to stay competitive in the market. In January 2020, Scotland approved a new prostate cancer drug for the men diagnosed with metastatic prostate cancer. The drug is Abiraterone acetate, branded name Zytiga owned by Centocor Ortho Biotech Inc., a company of Johnson & Johnson.

Research Methodology

The market study is incorporated by extensive primary and secondary research conducted by the research team.  Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. In the report, the analysis of the country is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts to brings authenticity to the reports.

Secondary Sources Include

• Financial reports of companies involved in the market.
• Whitepapers, research-papers, and news blogs.
• Company websites and their product catalog.

The report is intended for drug manufacturing companies, medical device manufacturing companies, contract manufacturers, government organizations, and venture capitalists for the comprehensive market analysis. The report provides an in-depth analysis on market size, intended quality of the service preferred by consumers. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. UK Prostate Cancer Market Research and Analysis by Diagnostic Technique
2. UK Prostate Cancer Market Research and Analysis by Therapy

The Report Covers

• Comprehensive research methodology of UK Prostate Cancer Market.
• This report also includes a detailed and extensive market overview with key analyst insights.
• An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting UK Prostate Cancer Market.
• Insights about market determinants which are stimulating UK Prostate Cancer Market.
• Detailed and extensive market segments with regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.